Bruker Co. (NASDAQ:BRKR - Free Report) - Equities research analysts at Zacks Research upped their FY2027 earnings per share (EPS) estimates for Bruker in a research note issued on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the medical research company will earn $3.61 per share for the year, up from their previous estimate of $3.60. The consensus estimate for Bruker's current full-year earnings is $2.69 per share.
Other research analysts have also recently issued research reports about the company. Stifel Nicolaus dropped their price objective on Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research note on Friday, February 14th. Bank of America increased their price objective on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, December 13th. UBS Group started coverage on Bruker in a research note on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price objective on the stock. The Goldman Sachs Group raised Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price objective on the stock in a research note on Thursday, December 5th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Bruker in a research report on Monday, February 24th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Bruker currently has an average rating of "Moderate Buy" and an average target price of $70.50.
Read Our Latest Stock Report on BRKR
Bruker Trading Up 2.1 %
NASDAQ:BRKR traded up $0.97 during midday trading on Thursday, hitting $46.94. The stock had a trading volume of 1,329,770 shares, compared to its average volume of 1,283,588. Bruker has a one year low of $44.11 and a one year high of $94.86. The company has a market capitalization of $7.12 billion, a price-to-earnings ratio of 61.76, a PEG ratio of 2.16 and a beta of 1.18. The stock has a 50-day moving average of $53.66 and a 200 day moving average of $58.36. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15.
Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%.
Bruker Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Monday, March 17th will be given a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.43%. Bruker's payout ratio is 26.32%.
Hedge Funds Weigh In On Bruker
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BRKR. True Wealth Design LLC raised its stake in Bruker by 4,636.4% in the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock worth $36,000 after acquiring an additional 510 shares during the last quarter. Eagle Bay Advisors LLC raised its stake in Bruker by 2,324.1% in the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock worth $41,000 after acquiring an additional 674 shares during the last quarter. UMB Bank n.a. raised its stake in Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after acquiring an additional 248 shares during the last quarter. GAMMA Investing LLC raised its stake in Bruker by 47.5% in the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock worth $75,000 after acquiring an additional 412 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its stake in Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after acquiring an additional 196 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.
About Bruker
(
Get Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Stories
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
